Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 44.95% | -50.37% | 28.49% | -19.81% | -4.56% |
| Total Depreciation and Amortization | -57.81% | 3.23% | 0.00% | 1.09% | 5.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -71.63% | 22.02% | -29.57% | 17.55% | 155.65% |
| Change in Net Operating Assets | 539.02% | 118.92% | -0.15% | -193.10% | 558.60% |
| Cash from Operations | 42.96% | -44.23% | 25.45% | -52.87% | 34.02% |
| Capital Expenditure | 93.86% | -1,454.55% | 0.00% | 53.19% | 43.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 93.86% | -1,454.55% | 0.00% | 53.19% | 43.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -83.23% | -7.41% | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -159.20% | -- | -- | -- |
| Cash from Financing | -82.17% | -12.31% | 110,515.84% | -168.24% | 254.17% |
| Foreign Exchange rate Adjustments | 38.16% | 142.42% | -240.32% | 166.12% | -439.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -124.92% | -35.96% | 247.22% | -29.52% | 27.44% |